Active Ingredient(s):Faricimab-svoa FDA Approved: * January 28, 2022 Pharm Company: *GENENTECH INC Category:Vision / Eye Health
Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2) inhibitor. By targeting these pathways, faricimab stabilizes blood vessels in t...
* May have multiple approval dates, manufacturers, or labelers.